左西孟旦治疗射血分数下降心力衰竭患者的临床疗效及对血流动力学、NT-proBNP水平的影响分析  

Clinical efficacy of levosimendan in the treatment of heart failure patients with reduced ejection fraction and its influence on hemodynamics and NT-proBNP level

作　　者：马素香 陈冬冬 张丽娜 谢琛玺 MA Su-xiang;CHEN Dong-dong;ZHANG Li-na(Department of Cardiovascular Medicine,Anxi County Hospital,Quanzhou 362400,China)

机构地区：[1]泉州市安溪县医院心血管内科,362400

出　　处：《中国现代药物应用》2025年第7期90-93,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析左西孟旦治疗射血分数下降心力衰竭患者的临床疗效及对血流动力学、氨基末端B型利钠肽前体(NT-proBNP)水平的影响。方法70例射血分数下降心力衰竭患者,按治疗方法不同分为对照组和观察组,各35例。对照组接受常规治疗,观察组在对照组接受左西孟旦治疗。对比两组患者的临床疗效、血流动力学指标、NT-proBNP水平及不良反应发生率。结果观察组总有效率比对照组高(97.14%VS 77.14%)(P<0.05)。治疗前,两组心排血指数(CI)、心输出量(CO)、每搏输出量指数(SVI)、每搏输出量(SV)对比没有差异(P>0.05);治疗后,两组CO与SV对比没有差异(P>0.05),观察组CI(3.79±0.75)L/(min·m^(2))与SVI(46.52±15.25)ml/m^(2)高于对照组的(3.21±0.54)L/(min·m^(2))、(34.58±15.25)ml/m^(2)(P<0.05)。治疗前,两组NT-proBNP水平对比没有差异(P>0.05);治疗后,观察组NT-proBNP(1268.25±213.25)pg/ml低于对照组的(1923.25±205.36)pg/ml(P<0.05)。观察组不良反应发生率5.71%比对照组的22.86%低(P<0.05)。结论对射血分数下降心力衰竭患者使用左西孟旦治疗,其临床疗效更理想,血流动力学指标明显改善,NT-proBNP水平显著降低,且不良反应少,值得在临床上广泛使用。Objective To analyze the clinical efficacy of levosimendan in the treatment of heart failure patients with reduced ejection fraction and its influence on hemodynamics and N-terminal pro-B-type natriuretic peptide(NT-proBNP)level.Methods 70 cases of heart failure patients with reduced ejection fraction were divided into control group and observation group according to different treatment methods,each with 35 cases.The control group received conventional treatment,and the observation group received levosimendan treatment based on the control group.The clinical efficacy,hemodynamic indices,NT-proBNP level and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(97.14%VS 77.14%)(P<0.05).Before treatment,there were no differences in cardiac index(CI),cardiac output(CO),stroke volume index(SVI)and stroke volume(SV)between the two groups(P>0.05).After treatment,there was no difference in CO and SV between the two groups(P>0.05).The observation group had CI of(3.79±0.75)L/(min·m^(2))and SVI of(46.52±15.25)ml/m^(2),which were higher than(3.21±0.54)L/(min·m^(2))and(34.58±15.25)ml/m^(2)in the control group(P<0.05).Before treatment,there was no difference in NT-proBNP level between the two groups(P>0.05).After treatment,the observation group had a lower NT-proBNP of(1268.25±213.25)pg/ml than(1923.25±205.36)pg/ml in the control group(P<0.05).The observation group had a lower incidence of adverse reactions of 5.71%than 22.86%in the control group(P<0.05).Conclusion The use of levosimendan in the treatment of heart failure patients with reduced ejection fraction has resulted in a more favorable clinical outcome,with significant improvement in hemodynamic indices,a significant reduction in NT-proBNP levels,and a reduction in adverse reactions,and is worthy of widespread clinical use.

关 键 词：左西孟旦 射血分数下降心力衰竭 血流动力学 氨基末端B型利钠肽前体 

分 类 号：R541.6[医药卫生—心血管疾病]